Deprescribing in dermatology

Journal of Dermatological Treatment · Available online 10 Apr 2026 · In press · DOI 10.1080/09546634.2026.2654941

Authors being retrieved — see the publisher record. https://doi.org/10.1080/09546634.2026.2654941

Abstract

DOAJ holds no abstract for this record.

Read the article at the publisher →

Publication details

Year: 2026

Related articles

Raising the bar of efficacy in Atopic Dermatitis: deep response in week 16 responders treated with lebrikizumab over 2 years · Journal of Dermatological Treatment · 2026 · Same journal
Comparative efficacy and safety of platelet-rich plasma (PRP), injectable platelet-rich fibrin (i-PRF) and concentrated growth factors (CGF) for female pattern hair loss (FPHL): a prospective multicenter randomized clinical trial · Journal of Dermatological Treatment · 2026 · Same journal
Early response to ivarmacitinib and its impact on long-term efficacy in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of a phase-III trial · Journal of Dermatological Treatment · 2026 · Same journal
Healthcare resource use of patients with mild-moderate psoriasis on systemic treatments: a UK single-center longitudinal retrospective cohort study · Journal of Dermatological Treatment · 2026 · Same journal
Effect of methotrexate on endothelial function in psoriasis patients · Journal of Dermatological Treatment · 2026 · Same journal
Evaluation of the clinical applicability of artificial intelligence in determining systemic therapy indications and treatment selection in psoriasis · Journal of Dermatological Treatment · 2026 · Same journal
Long-term benefits of upadacitinib for Atopic Dermatitis: deep responses in patient-reported outcomes over 140 weeks from the Measure Up 1 and Measure Up 2 clinical trials · Journal of Dermatological Treatment · 2026 · Same journal
Distinct ocular safety profiles of dupilumab and upadacitinib in atopic dermatitis: a real-world study with ophthalmological and microbiological assessment · Journal of Dermatological Treatment · 2026 · Same journal
Recalcitrant tinea infections due to Trichophyton indotineae in the United States (2025–2026): a retrospective case series identified by real-time PCR · Journal of Dermatological Treatment · 2026 · Same journal
Safety and effectiveness of omalizumab for chronic spontaneous urticaria inadequately controlled with H1 antihistamines in Chinese adolescents: a real-world, prospective, multicenter study · Journal of Dermatological Treatment · 2026 · Same journal